GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback